The malignant property of circHIPK2 for angiogenesis and chemoresistance in non-small cell lung cancer.

[1]  Wenhui Tao,et al.  Circular RNA circCPA4 promotes tumorigenesis by regulating miR‐214‐3p/TGIF2 in lung cancer , 2021, Thoracic cancer.

[2]  Shanfeng Zhang,et al.  Blocking circ-SCMH1 (hsa_circ_0011946) suppresses acquired DDP resistance of oral squamous cell carcinoma (OSCC) cells both in vitro and in vivo by sponging miR-338-3p and regulating LIN28B , 2021, Cancer cell international.

[3]  Junguang Jiang,et al.  Circ_0006988 promotes the proliferation, metastasis and angiogenesis of non-small cell lung cancer cells by modulating miR-491-5p/MAP3K3 axis , 2021, Cell cycle.

[4]  Yang Cao,et al.  CircHIPK2 Contributes to DDP Resistance and Malignant Behaviors of DDP-Resistant Ovarian Cancer Cells Both in vitro and in vivo Through circHIPK2/miR-338-3p/CHTOP ceRNA Pathway , 2021, OncoTargets and therapy.

[5]  Rusong Yang,et al.  Alginic acid inhibits non-small cell lung cancer-induced angiogenesis via activating miR-506 expression , 2021, Journal of Natural Medicines.

[6]  Ho-Yyoung Lee,et al.  Mechanisms of resistance to chemotherapy in non-small cell lung cancer , 2021, Archives of Pharmacal Research.

[7]  Zhu Jin,et al.  Depletion of circ-BIRC6, a circular RNA, suppresses non-small cell lung cancer progression by targeting miR-4491. , 2020, Bioscience trends.

[8]  Ke Wang,et al.  Circular RNA hsa_circ_0096157 contributes to cisplatin resistance by proliferation, cell cycle progression, and suppressing apoptosis of non-small-cell lung carcinoma cells , 2020, Molecular and Cellular Biochemistry.

[9]  Y. Ling,et al.  CircRNA DONSON contributes to cisplatin resistance in gastric cancer cells by regulating miR-802/BMI1 axis , 2020, Cancer Cell International.

[10]  Mu Zhang,et al.  The circular RNA 001971/miR-29c-3p axis modulates colorectal cancer growth, metastasis, and angiogenesis through VEGFA , 2020, Journal of experimental & clinical cancer research : CR.

[11]  I. Wakabayashi,et al.  HDGF enhances VEGF-dependent angiogenesis and FGF-2 is a VEGF-independent angiogenic factor in non-small cell lung cancer , 2020, Oncology reports.

[12]  R. Guleria,et al.  Differential expression of circulating serum miR-1249-3p, miR-3195, and miR-3692-3p in non-small cell lung cancer , 2020, Human Cell.

[13]  N. Hanna,et al.  The Story of Angiogenesis Inhibitors in Non-small-cell Lung Cancer: The Past, Present, and Future. , 2020, Clinical lung cancer.

[14]  Xinwei Han,et al.  Circular RNA HIPK3 induces cell proliferation and inhibits apoptosis in non-small cell lung cancer through sponging miR-149 , 2020, Cancer biology & therapy.

[15]  Jørgen Kjems,et al.  The biogenesis, biology and characterization of circular RNAs , 2019, Nature Reviews Genetics.

[16]  Yolan J. Reckman,et al.  Circular RNAs open a new chapter in cardiovascular biology , 2019, Nature Reviews Cardiology.

[17]  Minhua Wu,et al.  Long non-coding RNA MIF-AS1 promotes breast cancer cell proliferation, migration and EMT process through regulating miR-1249-3p/HOXB8 axis. , 2019, Pathology, research and practice.

[18]  Zhaocai Zhou,et al.  Structure and Degradation of Circular RNAs Regulate PKR Activation in Innate Immunity , 2019, Cell.

[19]  T. Orlowski,et al.  The expression of circulating miR-504 in plasma is associated with EGFR mutation status in non-small-cell lung carcinoma patients , 2019, Cellular and Molecular Life Sciences.

[20]  Yu-qin Pan,et al.  P53-induced miR-1249 inhibits tumor growth, metastasis, and angiogenesis by targeting VEGFA and HMGA2 , 2019, Cell Death & Disease.

[21]  Yue Zhang,et al.  MicroRNA-1253 suppresses cell proliferation and invasion of non-small-cell lung carcinoma by targeting WNT5A , 2018, Cell Death & Disease.

[22]  Rafael Rosell,et al.  Genetics and biomarkers in personalisation of lung cancer treatment , 2013, The Lancet.

[23]  Michael M Gottesman,et al.  Cisplatin Resistance: A Cellular Self-Defense Mechanism Resulting from Multiple Epigenetic and Genetic Changes , 2012, Pharmacological Reviews.

[24]  D. Cheresh,et al.  Tumor angiogenesis: molecular pathways and therapeutic targets , 2011, Nature Medicine.

[25]  Quynh-Thu Le,et al.  Non-small cell lung cancer: Clinical practice guidelines in oncology , 2006 .

[26]  I. Judson,et al.  New Developments and Approaches in the Platinum Arena , 2012, Drugs.